CD95L concatemers highlight different stoichiometries of CD95-mediated apoptotic and nonapoptotic pathways.
Apoptosis
Calcium
Concatemer
Stoichiometry
TNF
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
14 Oct 2023
14 Oct 2023
Historique:
revised:
12
10
2023
received:
23
06
2023
accepted:
13
10
2023
pubmed:
15
10
2023
medline:
15
10
2023
entrez:
14
10
2023
Statut:
aheadofprint
Résumé
To better understand the stoichiometry of CD95L required to trigger apoptotic and nonapoptotic signals, we generated several CD95L concatemers from dimer to hexamer conjugated via a flexible link (GGGGS)
Identifiants
pubmed: 37837385
doi: 10.1002/eji.202350626
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2350626Subventions
Organisme : INCa PLBIO
ID : PLBIO 2018-132
Organisme : ANR
ID : ANR-22-CE15-0038-02
Organisme : ANR
ID : PCSI 2021 (CD95L-ProbInnov)
Organisme : Fondation de France
ID : Price Jean Valade
Organisme : PCSI
Organisme : Institut National Du Cancer
ID : PLBIO 2018-132
Informations de copyright
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
Strasser, A., Jost, P. J. and Nagata, S., The many roles of FAS receptor signaling in the immune system. Immunity 2009. 30: 180-192.
Levoin, N., Jean, M. and Legembre, P., CD95 structure, aggregation and cell signaling. Front. Cell Dev. Biol. 2020. 8: 314.
Schneider, P., Holler, N., Bodmer, J. L., Hahne, M., Frei, K., Fontana, A. and Tschopp, J., Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 1998. 187: 1205-1213.
Tauzin, S., Chaigne-Delalande, B., Selva, E., Khadra, N., Daburon, S., Contin-Bordes, C., Blanco, P. et al., The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol. 2011. 9: e1001090.
Chinnaiyan, A. M., O'Rourke, K., Tewari, M. and Dixit, V. M., FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995. 81: 505-512.
Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H. and Peter, M. E., Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J. 1995. 14: 5579-5588.
Chinnaiyan, A. M., Tepper, C. G., Seldin, M. F., O'Rourke, K., Kischkel, F. C., Hellbardt, S., Krammer, P. H. et al., FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem. 1996. 271: 4961-4965.
Steller, E. J., Ritsma, L., Raats, D. A., Hoogwater, F. J., Emmink, B. L., Govaert, K. M., Laoukili, J. et al., The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. EMBO Rep. 2011. 12: 931-937.
Emrich, S. M., Yoast, R. E. and Trebak, M., Physiological functions of CRAC channels. Annu. Rev. Physiol. 2022. 84: 355-379.
Holler, N., Tardivel, A., Kovacsovics-Bankowski, M., Hertig, S., Gaide, O., Tinel, A., Deperthes, D. et al., Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell. Biol. 2003. 23: 1428-1440.
Poissonnier, A., Sanseau, D., Le Gallo, M., Malleter, M., Levoin, N., Viel, R., Morere, L. et al., CD95-mediated calcium signaling promotes T helper 17 trafficking to inflamed organs in lupus-prone mice. Immunity 2016. 45: 209-223.
Herrero, R., Kajikawa, O., Matute-Bello, G., Wang, Y., Hagimoto, N., Mongovin, S., Wong, V. et al., The biological activity of FasL in human and mouse lungs is determined by the structure of its stalk region. J. Clin. Invest. 2011. 121: 1174-1190.
Devel, L., Guedeney, N., Bregant, S., Chowdhury, A., Jean, M. and Legembre, P., Role of metalloproteases in the CD95 signaling pathways. Front. Immunol. 2022. 13: 1074099.
Lavrik, I. N., Golks, A., Riess, D., Bentele, M., Eils, R. and Krammer, P. H., Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J. Biol. Chem. 2007. 282: 13664-13671.
Legembre, P., Barnhart, B. C., Zheng, L., Vijayan, S., Straus, S. E., Puck, J., Dale, J. K. et al., Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep. 2004. 5: 1084-1089.
Lang, I., Fick, A., Schafer, V., Giner, T., Siegmund, D. and Wajant, H., Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts. J. Biol. Chem. 2012. 287: 24026-24042.
Berg, D., Lehne, M., Muller, N., Siegmund, D., Munkel, S., Sebald, W., Pfizenmaier, K. et al., Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ. 2007. 14: 2021-2034.
Schneider, P., Bodmer, J. L., Holler, N., Mattmann, C., Scuderi, P., Terskikh, A., Peitsch, M. C. et al., Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J. Biol. Chem. 1997. 272: 18827-18833.
Liu, W., Ramagopal, U., Cheng, H., Bonanno, J. B., Toro, R., Bhosle, R., Zhan, C. et al., Crystal structure of the complex of human FasL and its decoy receptor DcR3. Structure 2016. 24: 2016-2023.
Kajikawa, O., Herrero, R., Chow, Y. H., Hung, C. F. and Matute-Bello, G., The bioactivity of soluble Fas ligand is modulated by key amino acids of its stalk region. PLoS One 2021. 16: e0253260.
Malleter, M., Tauzin, S., Bessede, A., Castellano, R., Goubard, A., Godey, F., Leveque, J. et al., CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res. 2013. 73: 6711-6721.
Poissonnier, A., Guegan, J. P., Nguyen, H. T., Best, D., Levoin, N., Kozlov, G., Gehring, K. et al., Disrupting the CD95-PLCgamma1 interaction prevents Th17-driven inflammation. Nat. Chem. Biol. 2018. 14: 1079-1089.
Vargo-Gogola, T., Crawford, H. C., Fingleton, B. and Matrisian, L. M., Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch. Biochem. Biophys. 2002. 408: 155-161.
Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K. et al., Fas ligand in human serum. Nat. Med. 1996. 2: 317-322.
Suda, T., Hashimoto, H., Tanaka, M., Ochi, T. and Nagata, S., Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 1997. 186: 2045-2050.